News

Erythromycin in babies and infants has been associated with an increased risk of infantile hypertrophic pyloric stenosis.

Experts from 13 national bodies, including seven Royal Colleges, have joined forces to launch new practical guidance to support doctors and other health professionals around valproate use in women and girls in their reproductive years.

This guidance, updated in December 2020 and endorsed by RCPCH, has been produced to inform all healthcare professionals of best practice around the use and prescribing of valproate. It supports them to navigate situations that could arise as a result of prescribing valproate to women during childbea...

The Epilepsy12 Youth Advocates have been selected as joint winners in the HQIP Audit Heroes Awards 2020 in the Volunteer of the Year Category, recognising their hard work to support improvements in epilepsy care.

Dr Colin Dunkley, Consultant Paediatrician and Clinical Lead for Epilepsy12 tells us about the recent report on the clinical and organisational aspects of epilepsies care for children and young people in England and Wales.

Health visitors fear the needs of vulnerable children have been missed due to staff redeployment to support the COVID-19 workforce, according to a new UCL survey.

RCPCH today publishes its first report from Paediatrics 2040, a major project looking at how paediatrics will change over the next 20 years.

The RCPCH has today published State of Child Health 2020, the largest ever compilation of data on the health of babies, children and young people across all four UK nations. The report shows that for many measures of children’s health and wellbeing, progress has stalled, or is in reverse – something...

Dr Mike Linney, Registrar and Chair of the Ethics Committee for RCPCH, welcomes recent guidance from NICE, but notes the urgent need for high quality, independent research on this medicine to provide the best possible care for children with complex epilepsy.

Last week, NICE published draft recommendations on the use of cannabis-based medicinal products (CBMPs) following evaluation of their clinical and cost-effectiveness, and NHS England published a review aimed at assessing the barriers to prescribing cannabis-based medicinal products where it is safe ...